Pierre Hainaut is the CEO of Institute for Advanced Biosciences. Hainaut is based in France. Hainaut was educated at University of Liège.
Recent developments
AI summary of recent coverageRecent coverage of Pierre Hainaut's research has focused on the role of TP53 gene variants in cancer risk and tumor development, including studies on how specific genetic alterations affect mRNA splicing patterns and phenotypic diversity among germline carriers. Publications have also examined the broader functions of TP53 beyond its classical role as a tumor suppressor, as well as molecular mechanisms driving cancer progression in conditions such as breast cancer metastasis and multiple myeloma across different populations.
Summarized from the headlines below; see each source for the full story.
Key Facts
Source: Wikidata ↗- Education
- University of Liège
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Pierre Hainaut, it will appear here — and tie into the news timeline.
In the News
7 stories- Nature·
Tumor patterns and cancer risk in carriers of TP53 exonic germline variants that alter mRNA splicing
- Nature·
The TP53 gene contains a diversity box that makes it more than a tumor suppressor
- Nature·
The legacy of a gentleman scientist: Pierre Hainaut - Cell Death & Differentiation
- Nature·
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup
- IARC – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER·
Pierre Hainaut (22 March 1958–31 July 2025)
- Nature·
Author Correction: Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis
- Nature·
Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent
Pierre Hainaut: FAQ
- What company does Pierre Hainaut lead?
- Pierre Hainaut is CEO of Institute for Advanced Biosciences.
- Where was Pierre Hainaut educated?
- Pierre Hainaut studied at University of Liège.